- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
48 result(s) found for: 549.
Displaying page 1 of 3.
| EudraCT Number: 2007-007953-30 | Sponsor Protocol Number: cv-07/126 | Start Date*: 2008-02-11 |
| Sponsor Name:Fundación Investigación y Desarrollo en el Área Cardiovascular | ||
| Full Title: Levosimendan como agente inmunomodulador en la insuficiencia cardiaca aguda. Estudio Piloto Levosimendan as an immunomodulatory agent in acute heart failure. Pilot study. | ||
| Medical condition: Analysis of the short-term treatment with levosimendan, a cardiac stimulant drug, of the acute exacerbation of chronic heart failure Estudio del tratamiento a corto plazo con levosimendan, fármac... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002060-31 | Sponsor Protocol Number: WHOCOVID-19coreprotocol | Start Date*: 2020-06-22 |
| Sponsor Name:Masaryk University | ||
| Full Title: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002177-35 | Sponsor Protocol Number: GNB-2015 | Start Date*: 2018-05-07 |
| Sponsor Name:Masarykova univerzita | ||
| Full Title: The effect of gabapentin used as a preemptive to the emergence and development chronic neuropathic pain in patients after spinal cord trauma | ||
| Medical condition: Chronic neuropathic pain in patients after spinal cord trauma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002753-22 | Sponsor Protocol Number: FAVID-01-20-SP | Start Date*: 2020-09-02 | |||||||||||
| Sponsor Name:Ferrer Internacional, S.A. | |||||||||||||
| Full Title: Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia −A randomized, double blind, placebo- controlled study − | |||||||||||||
| Medical condition: Patients diagnosed with COVID-19 by positive PCR for SARS-COV2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-005139-61 | Sponsor Protocol Number: EB064 | Start Date*: 2006-10-24 |
| Sponsor Name:Emotional Brain | ||
| Full Title: Neural correlates of sexual arousal during treatment of testosterone combined with sildenafil in healthy female subjects with FSD. Effects of differing levels of attentional engagement on neural co... | ||
| Medical condition: Hypoactive sexual desire disorder and female sexual arousal disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-000257-56 | Sponsor Protocol Number: EB065 | Start Date*: 2007-02-05 |
| Sponsor Name:Emotional Brain BV | ||
| Full Title: Neural correlates of sexual arousal during treatment of testosterone combined with sildenafil in healthy female subjects with FSD. Effects of differing levels of attentional engagement on neural co... | ||
| Medical condition: Hypoactive sexual desire disorder and female sexual arousal disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-003088-76 | Sponsor Protocol Number: 11-170 | Start Date*: 2014-07-14 |
| Sponsor Name:Clinical Evaluation Research Unit (CERU) | ||
| Full Title: SodiUm SeleniTe Adminstration IN Cardiac Surgery surgery (SUSTAIN CSX®-trial) - A randomized controlled trial of high dose sodium-selenite administration in high risk cardiac surgical patients | ||
| Medical condition: Selenium is a key component of a number of selenoproteins which protect against oxidative stress and is well recognised for its prominent role in immune defence. Selenoproteins have the potential t... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-002267-25 | Sponsor Protocol Number: SEOTP-2018 | Start Date*: 2018-07-18 |
| Sponsor Name:Fakultní nemocnice Brno | ||
| Full Title: SAFETY AND EFFICACY OF OLANZAPINE TREATMENT IN PSYCHOSIS: EFFECT OF GENETIC AND EPIGENETIC FACTORS – COVARIATES OF TREATMENT RESPONSE | ||
| Medical condition: Psychoses | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-003370-41 | Sponsor Protocol Number: VAT00002 | Start Date*: 2021-08-23 | |||||||||||
| Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
| Full Title: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SA... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005717-80 | Sponsor Protocol Number: FAB117-CT-01 | Start Date*: 2016-05-29 | ||||||||||||||||
| Sponsor Name:Ferrer Internacional S.A | ||||||||||||||||||
| Full Title: Clinical trial of phase 1/2 to evaluate the feasibility, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogeneic adipos... | ||||||||||||||||||
| Medical condition: Patients with acute traumatic spinal cord injury | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-004550-33 | Sponsor Protocol Number: APHP211184 | Start Date*: 2021-11-15 |
| Sponsor Name:Assistance publique Hopitaux de Paris/ DRCI | ||
| Full Title: Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pf... | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-003388-39 | Sponsor Protocol Number: KDO_DC1311 | Start Date*: 2015-03-26 |
| Sponsor Name:Masarykova univerzita | ||
| Full Title: COMBINED ANTITUMOR THERAPY WITH EX VIVO MANIPULATED DENDRITIC CELLS PRODUCING INTERLEUKIN-12 IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH PROGRESSIVE, RECURRENT OR PRIMARILY METASTATIC HIGH-RISK ... | ||
| Medical condition: Progressive, recurrent or primarily metastatic high-risk malignities | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: CZ (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000228-52 | Sponsor Protocol Number: P-110881-01 | Start Date*: 2014-06-03 |
| Sponsor Name:Ferrer Internacional, SA | ||
| Full Title: A phase III 2 arms, multicenter, randomised, double-blind study to assess the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patients w... | ||
| Medical condition: Impetigo | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) RO (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-003331-36 | Sponsor Protocol Number: FER-Loxapine-2015-01 | Start Date*: 2016-03-16 | |||||||||||
| Sponsor Name:FERRER INTERNACIONAL SA | |||||||||||||
| Full Title: A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of self-administered ADASUVE(R) (Staccato loxapine for inhalation) in Agitated Patients outside the hospital setting | |||||||||||||
| Medical condition: Mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) NO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-001281-13 | Sponsor Protocol Number: KS-2004-06-SET | Start Date*: 2005-11-15 |
| Sponsor Name:DSC Services, s.r.o. | ||
| Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study) | ||
| Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-003827-19 | Sponsor Protocol Number: P051021 | Start Date*: 2007-11-09 |
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
| Full Title: Efficacité comparative de l'éradication de H.pylori et d'un inhibiteur de pompe à proton vs. l'abstention thérapeutique sur lésions gastriques induite par l'aspirine à faible dose chez les malades ... | ||
| Medical condition: lésions ulcérées gastriques chez les malades traités au long cours par aspirine en prévention d'une thrombose coronaire ou vasculaire cérébrale. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001966-87 | Sponsor Protocol Number: FCD-LOR-1402 | Start Date*: 2015-07-30 | |||||||||||
| Sponsor Name:FERRER INTERNACIONAL, S.A. | |||||||||||||
| Full Title: Double-blind, randomized, placebo-controlled cross-over dose finding study of two doses of lorediplon in adult patients with insomnia disorder | |||||||||||||
| Medical condition: Insomnia disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) HR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001982-36 | Sponsor Protocol Number: AcT_CZE | Start Date*: 2020-08-19 | ||||||||||||||||
| Sponsor Name:Fakultní nemocnice u sv. Anny | ||||||||||||||||||
| Full Title: Alteplase compared to tenecteplase in patients with acute ischemic stroke: Registry-based pragmatic randomized controlled trial | ||||||||||||||||||
| Medical condition: Acute ischemic stroke | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: CZ (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2006-000562-36 | Sponsor Protocol Number: BIG2-06/N063D/EGF106708 | Start Date*: 2007-05-04 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their comb... | |||||||||||||
| Medical condition: Operable primary breast cancer with over expression/ amplification of HER2. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Completed) HU (Completed) FR (Completed) GB (Completed) SK (Completed) EE (Completed) CZ (Completed) DK (Completed) BE (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed) ES (Completed) SI (Completed) BG (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001210-15 | Sponsor Protocol Number: MOU-2017-02 | Start Date*: 2018-11-19 |
| Sponsor Name:Masarykův onkologický ústav | ||
| Full Title: Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) | ||
| Medical condition: inoperable, untreated, wild type RAS (wt KRAS/wtNRAS), metastatic colorectal cancer (mCRC) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
